Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EOL-101
- Development stage
- Preclinical
- Lead developer
- Eolas Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EOL-101 (also known as EORA-101) is an investigational small molecule orexin-1 receptor (OX1R) antagonist being developed by Eolas Therapeutics. It is designed to target neural pathways within the brain's reward system to treat substance use disorders, with a primary focus on nicotine addiction and smoking cessation. By selectively blocking the downstream OX1R localized in the hypothalamus, EOL-101 aims to directly modulate the motivational properties of addiction and prevent cue-induced relapse without causing the side effects associated with upstream nicotine receptor blockers or dual orexin receptor antagonists.
02
Targets
HCRTR1 (Orexin/hypocretin receptor type 1)
Beyond the preview
Go deeper on EOL-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EOL-101.